Fierce Healthcare December 7, 2022
By Alison Lum, Edward Fotsch

This is the third in a series of articles that looks at the current state of drug cost transparency for prescribers, pharmacists, and patients. The first two articles can be found here and here.

The first and second articles in this series focused on the promise and challenges with real-time prescription benefit (RTPB), including the need to move beyond transparency solely when ordering new prescriptions through the electronic health record.

This third article expands the focus of drug cost transparency to include all of a patient’s current medications and all relevant points of patient care and communications. While cost transparency to prescribers in EHRs is essential, there are many other relevant and important stakeholders in the care...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth
2024 Pharm Exec Top 50 Companies
Federal Support Should Not Be A Factor In Determining Pharmaceutical Prices Under The IRA
Chutes & Ladders—Longtime J&J exec retiring after 17 years
Pharma Pulse 6/14/24: GLP-1 Drugs Changed the Paradigm in Weight Loss, What’s Coming to Apple Devices & more

Share This Article